ESCMID eAcademy

ePosters are only viewable by those with a valid ECCMID 2021 registration.
If you already have a registration, please login to the online platform here.
If you are not yet registered, you can do so here.
Abstract
Discussion Forum (0)
Abstract number: 1143

Session Type: ePosters

Session Title: ePosters

Authors(s): C. Sigera (1), C. Rodrigo (2), N.L. De Silva (3), P. Weeratunga (4), S.D. Fernando (1), S. Rajapakse (4)

Authors Affiliations(s): (1) Department of Parasitology, Faculty of Medicine, University of Colombo, Sri Lanka, Sri Lanka, (2) Department of Pathology, School of Medical Sciences, UNSW Sydney, 2052, NSW, Australia, Australia, (3) Department of Clinical Medicine, Faculty of Medicine, Sir John Kotelawala Defence University, Ratmalana, Sri Lanka, Sri Lanka, (4) Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Sri Lanka, Sri Lanka

Background:

The cost in managing hospitalised dengue patients vary across countries depending on access to healthcare, management guidelines, availability of diagnostic tests and state sponsored subsidies. Hence for health budget planning and cost reduction, locally relevant, accurate costing data from prospective studies, is essential. A comprehensive, recent analysis of costs associated with monitoring Sri Lankan dengue patients in hospitals is unavailable except for few limited datasets (less than 150 patients).

Methods:

Colombo Dengue Study (CDS) is a prospective single centre cohort study in Sri Lanka that recruits hospitalised dengue patients in the first three days of fever and follows them up until death / discharge. The diagnosis of dengue is retrospectively confirmed and therefore the cohort also have non-dengue fever patients with a phenotypically similar illness, managed as dengue while in hospital. The direct costs of hospital admission (base and investigation costs, excluding medication) were calculated for all recruited patients and compared between dengue (DF) and non-dengue fever (NDF) patients as well as other subgroups based on demographic, clinical or temporal characteristics.

Results:

Over 29 months, a total of 431 (males – 285, 66.1%, mean age: 31.4 years) confirmed DF patients and 256 NDF patients (males –176, 68.8%, mean age: 37.7 years) were recruited between October 2017 to February 2020. The standardised hospitalisation costs were USD 18.02 (SD: 4.42) and USD 17.55 (SD: 4.09) per patient per day for DF and NDF patients respectively. There was no significant difference of daily cost or for the cost of total stay (based on the average duration of stay) between these groups (p>0.05). Investigations accounted for more than 50% of the total cost. The costs were also largely homogenous in all subgroups within or across DF and NDF categories.

 

Conclusions:

This single centre prospective study conducted over two and half years (2017 – 2020) demonstrates NDF patients incur the same cost as DF patients, investing in better diagnostic services may lead to overall cost savings through early confirmation and less intensive monitoring of NDF patients. The costs were largely homogenous across different subgroups based on demographic, clinical and temporal characteristics.  

Keyword(s): Cost, Dengue, Diagnostic tests

COI Institutional Grants: Yes
Abstract number: 1143

Session Type: ePosters

Session Title: ePosters

Authors(s): C. Sigera (1), C. Rodrigo (2), N.L. De Silva (3), P. Weeratunga (4), S.D. Fernando (1), S. Rajapakse (4)

Authors Affiliations(s): (1) Department of Parasitology, Faculty of Medicine, University of Colombo, Sri Lanka, Sri Lanka, (2) Department of Pathology, School of Medical Sciences, UNSW Sydney, 2052, NSW, Australia, Australia, (3) Department of Clinical Medicine, Faculty of Medicine, Sir John Kotelawala Defence University, Ratmalana, Sri Lanka, Sri Lanka, (4) Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Sri Lanka, Sri Lanka

Background:

The cost in managing hospitalised dengue patients vary across countries depending on access to healthcare, management guidelines, availability of diagnostic tests and state sponsored subsidies. Hence for health budget planning and cost reduction, locally relevant, accurate costing data from prospective studies, is essential. A comprehensive, recent analysis of costs associated with monitoring Sri Lankan dengue patients in hospitals is unavailable except for few limited datasets (less than 150 patients).

Methods:

Colombo Dengue Study (CDS) is a prospective single centre cohort study in Sri Lanka that recruits hospitalised dengue patients in the first three days of fever and follows them up until death / discharge. The diagnosis of dengue is retrospectively confirmed and therefore the cohort also have non-dengue fever patients with a phenotypically similar illness, managed as dengue while in hospital. The direct costs of hospital admission (base and investigation costs, excluding medication) were calculated for all recruited patients and compared between dengue (DF) and non-dengue fever (NDF) patients as well as other subgroups based on demographic, clinical or temporal characteristics.

Results:

Over 29 months, a total of 431 (males – 285, 66.1%, mean age: 31.4 years) confirmed DF patients and 256 NDF patients (males –176, 68.8%, mean age: 37.7 years) were recruited between October 2017 to February 2020. The standardised hospitalisation costs were USD 18.02 (SD: 4.42) and USD 17.55 (SD: 4.09) per patient per day for DF and NDF patients respectively. There was no significant difference of daily cost or for the cost of total stay (based on the average duration of stay) between these groups (p>0.05). Investigations accounted for more than 50% of the total cost. The costs were also largely homogenous in all subgroups within or across DF and NDF categories.

 

Conclusions:

This single centre prospective study conducted over two and half years (2017 – 2020) demonstrates NDF patients incur the same cost as DF patients, investing in better diagnostic services may lead to overall cost savings through early confirmation and less intensive monitoring of NDF patients. The costs were largely homogenous across different subgroups based on demographic, clinical and temporal characteristics.  

Keyword(s): Cost, Dengue, Diagnostic tests

COI Institutional Grants: Yes
Direct costs of managing hospitalised dengue patients in Sri Lanka: a prospective study
Mrs. Ponsuge Chathurani Sigera
Mrs. Ponsuge Chathurani Sigera
ESCMID eAcademy. Sigera P. 07/09/2021; 327987; 1143
user
Mrs. Ponsuge Chathurani Sigera
Abstract
Discussion Forum (0)
Abstract number: 1143

Session Type: ePosters

Session Title: ePosters

Authors(s): C. Sigera (1), C. Rodrigo (2), N.L. De Silva (3), P. Weeratunga (4), S.D. Fernando (1), S. Rajapakse (4)

Authors Affiliations(s): (1) Department of Parasitology, Faculty of Medicine, University of Colombo, Sri Lanka, Sri Lanka, (2) Department of Pathology, School of Medical Sciences, UNSW Sydney, 2052, NSW, Australia, Australia, (3) Department of Clinical Medicine, Faculty of Medicine, Sir John Kotelawala Defence University, Ratmalana, Sri Lanka, Sri Lanka, (4) Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Sri Lanka, Sri Lanka

Background:

The cost in managing hospitalised dengue patients vary across countries depending on access to healthcare, management guidelines, availability of diagnostic tests and state sponsored subsidies. Hence for health budget planning and cost reduction, locally relevant, accurate costing data from prospective studies, is essential. A comprehensive, recent analysis of costs associated with monitoring Sri Lankan dengue patients in hospitals is unavailable except for few limited datasets (less than 150 patients).

Methods:

Colombo Dengue Study (CDS) is a prospective single centre cohort study in Sri Lanka that recruits hospitalised dengue patients in the first three days of fever and follows them up until death / discharge. The diagnosis of dengue is retrospectively confirmed and therefore the cohort also have non-dengue fever patients with a phenotypically similar illness, managed as dengue while in hospital. The direct costs of hospital admission (base and investigation costs, excluding medication) were calculated for all recruited patients and compared between dengue (DF) and non-dengue fever (NDF) patients as well as other subgroups based on demographic, clinical or temporal characteristics.

Results:

Over 29 months, a total of 431 (males – 285, 66.1%, mean age: 31.4 years) confirmed DF patients and 256 NDF patients (males –176, 68.8%, mean age: 37.7 years) were recruited between October 2017 to February 2020. The standardised hospitalisation costs were USD 18.02 (SD: 4.42) and USD 17.55 (SD: 4.09) per patient per day for DF and NDF patients respectively. There was no significant difference of daily cost or for the cost of total stay (based on the average duration of stay) between these groups (p>0.05). Investigations accounted for more than 50% of the total cost. The costs were also largely homogenous in all subgroups within or across DF and NDF categories.

 

Conclusions:

This single centre prospective study conducted over two and half years (2017 – 2020) demonstrates NDF patients incur the same cost as DF patients, investing in better diagnostic services may lead to overall cost savings through early confirmation and less intensive monitoring of NDF patients. The costs were largely homogenous across different subgroups based on demographic, clinical and temporal characteristics.  

Keyword(s): Cost, Dengue, Diagnostic tests

COI Institutional Grants: Yes
Abstract number: 1143

Session Type: ePosters

Session Title: ePosters

Authors(s): C. Sigera (1), C. Rodrigo (2), N.L. De Silva (3), P. Weeratunga (4), S.D. Fernando (1), S. Rajapakse (4)

Authors Affiliations(s): (1) Department of Parasitology, Faculty of Medicine, University of Colombo, Sri Lanka, Sri Lanka, (2) Department of Pathology, School of Medical Sciences, UNSW Sydney, 2052, NSW, Australia, Australia, (3) Department of Clinical Medicine, Faculty of Medicine, Sir John Kotelawala Defence University, Ratmalana, Sri Lanka, Sri Lanka, (4) Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Sri Lanka, Sri Lanka

Background:

The cost in managing hospitalised dengue patients vary across countries depending on access to healthcare, management guidelines, availability of diagnostic tests and state sponsored subsidies. Hence for health budget planning and cost reduction, locally relevant, accurate costing data from prospective studies, is essential. A comprehensive, recent analysis of costs associated with monitoring Sri Lankan dengue patients in hospitals is unavailable except for few limited datasets (less than 150 patients).

Methods:

Colombo Dengue Study (CDS) is a prospective single centre cohort study in Sri Lanka that recruits hospitalised dengue patients in the first three days of fever and follows them up until death / discharge. The diagnosis of dengue is retrospectively confirmed and therefore the cohort also have non-dengue fever patients with a phenotypically similar illness, managed as dengue while in hospital. The direct costs of hospital admission (base and investigation costs, excluding medication) were calculated for all recruited patients and compared between dengue (DF) and non-dengue fever (NDF) patients as well as other subgroups based on demographic, clinical or temporal characteristics.

Results:

Over 29 months, a total of 431 (males – 285, 66.1%, mean age: 31.4 years) confirmed DF patients and 256 NDF patients (males –176, 68.8%, mean age: 37.7 years) were recruited between October 2017 to February 2020. The standardised hospitalisation costs were USD 18.02 (SD: 4.42) and USD 17.55 (SD: 4.09) per patient per day for DF and NDF patients respectively. There was no significant difference of daily cost or for the cost of total stay (based on the average duration of stay) between these groups (p>0.05). Investigations accounted for more than 50% of the total cost. The costs were also largely homogenous in all subgroups within or across DF and NDF categories.

 

Conclusions:

This single centre prospective study conducted over two and half years (2017 – 2020) demonstrates NDF patients incur the same cost as DF patients, investing in better diagnostic services may lead to overall cost savings through early confirmation and less intensive monitoring of NDF patients. The costs were largely homogenous across different subgroups based on demographic, clinical and temporal characteristics.  

Keyword(s): Cost, Dengue, Diagnostic tests

COI Institutional Grants: Yes

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies